Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Large Decline in Short Interest

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the target of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 10,660,000 shares, a drop of 19.4% from the September 15th total of 13,220,000 shares. Based on an average daily trading volume, of 667,100 shares, the short-interest ratio is currently 16.0 days. Approximately 9.4% of the company's shares are sold short.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Exchange Traded Concepts LLC grew its stake in shares of Lyell Immunopharma by 37.3% during the third quarter. Exchange Traded Concepts LLC now owns 135,050 shares of the company's stock worth $186,000 after acquiring an additional 36,715 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Lyell Immunopharma by 78.1% during the third quarter. SG Americas Securities LLC now owns 57,566 shares of the company's stock worth $79,000 after buying an additional 25,247 shares during the period. Susquehanna Fundamental Investments LLC raised its stake in shares of Lyell Immunopharma by 49.5% in the second quarter. Susquehanna Fundamental Investments LLC now owns 128,203 shares of the company's stock valued at $186,000 after acquiring an additional 42,452 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Lyell Immunopharma by 14.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 553,163 shares of the company's stock worth $802,000 after acquiring an additional 69,712 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Lyell Immunopharma by 197.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company's stock valued at $58,000 after purchasing an additional 26,635 shares during the last quarter. Hedge funds and other institutional investors own 66.05% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on LYEL shares. Bank of America decreased their price objective on Lyell Immunopharma from $9.00 to $6.00 and set a "buy" rating for the company in a report on Thursday, June 27th. HC Wainwright reissued a "neutral" rating and set a $1.00 price objective on shares of Lyell Immunopharma in a research note on Monday, August 19th.

Lyell Immunopharma Stock Performance

Shares of LYEL traded up $0.09 during mid-day trading on Friday, reaching $1.18. The stock had a trading volume of 428,028 shares, compared to its average volume of 899,109. Lyell Immunopharma has a 12 month low of $1.06 and a 12 month high of $3.26. The business has a fifty day moving average of $1.35 and a 200 day moving average of $1.88. The firm has a market cap of $300.83 million, a price-to-earnings ratio of -1.31 and a beta of -0.53.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.02. The company had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 389,368.50% and a negative return on equity of 33.35%. On average, research analysts forecast that Lyell Immunopharma will post -0.85 EPS for the current fiscal year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.